CASSS is pleased to announce a new collaboration between CASSS and the IQ Consortium. This year, representatives from the IQ Biologics CMC Leadership Group served as liaisons on the Scientific Organizing Committee, bringing deep industry insight and subject-matter expertise to forum planning. This collaboration directly informed the development of Workshop II – Right Dose, Real Impact: Strategies to Ensure Consistent Dose for Every Patient at CMC Strategy Forum North America that took place January 26. This Forum featured the work of the IQ Consortium Injectable Products Allowable Content Working Group. Resources and On Demand Video will be available to CASSS members in early March.
Together, CASSS and IQ are strengthening dialogue across industry, regulators, and standards organizations, enhancing the scientific rigor and relevance of forum content, with a shared commitment to continued collaboration in future forums.